Impact of induction therapy with anti-lymphocyte agents on long-term survival of kidney transplantation
10.3760/cma.j.issn.0254-1785.2011.06.009
- VernacularTitle:抗淋巴细胞制剂诱导治疗对肾移植后人、肾长期存活的影响
- Author:
Jian XU
;
Lixin YU
;
Chuanfu DU
;
Wenfeng DENG
;
Shaojie FU
;
Yibin WANG
;
Yun MIAO
;
Junsheng YE
;
Yuming YU
- Publication Type:Journal Article
- Keywords:
Kidney transplantation;
Induction therapy;
Antithymocyte globulin;
Basiliximab
- From:
Chinese Journal of Organ Transplantation
2011;32(6):355-357
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the impact of induction therapy with anti-lymphocyte agents on long-term survival of kidney transplantation.Methods 271 recipients of first cadaveric kidney transplants were treated with tacrolimus,mycophenolate mofetil and prednisone.110 patients of them received induction therapy with anti-thymocyte globulin(ATG group),88 patients received Basiliximab(Bax group),and the remaining 73 patients did not receive induction therapy(control group).The data of AR,DGF,CMV infection,and 1- 3- 5-year patient/allograft survival rate in three groups were retrospectively during a follow-up period of 1 to 5 years postoperatively.Results Within 6 months after operation,the incidence of AR in control group,ATG group and Bax group was 17.8 %(13/73),9.1 %(10/110)and 10.2 %(9/88)respectively.The incidence of AR in ATG group and Bax group was significantly lower than in control group (P<0.05).There was no significant difference in incidence of DGF and CMV infection among three groups.The 1-,3- and 5-year allograft survival rate postoperation in ATG group and Bax group was 95.5 %,90.9 %,87.3 % and 93.2 %,87.5 %,83.8 % respectively,which was significantly higher than in control group(87.7 %,80.8 % and 75.3 %,P<0.05).Conclusion Induction therapy with anti-lymphocyte agents may reduce the early incidence of AR and prolong long-term allograft survival significantly.
